Baseline retinal vascular bed area on ultra-wide field fluorescein angiography correlates with the anatomical outcome of diabetic macular oedema to ranibizumab therapy: two-year analysis of the DAVE Study

Wenying Fan, Akihito Uji, Charles C. Wykoff, David M. Brown, Jano van Hemert, Khalil Ghasemi Falavarjani, Kang Wang, Srini Vas R. Sadda, Michael Ip

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To determine the relationship between baseline retinal non-perfusion area (NPA) and retinal vascular bed area (RVBA) on ultra-wide field fluorescein angiography (UWF FA) and long-term response to intravitreal ranibizumab therapy in diabetic macular oedema (DMO). Methods: A post-hoc, 2-year observational case series. Baseline UWF FA images (Optos 200Tx) of 40 eyes from 29 patients with diabetes mellitus and treatment naïve DMO in the DAVE (NCT01552408) study were montaged and stereographically projected at the Doheny Image Reading Center to adjust for peripheral distortion. The retinal vasculature was automatically extracted to calculate RVBA. NPA was manually delineated by two masked certified graders. RVBA and NPA were computed in mm2 automatically by adjusting for peripheral distortion and then correlated with the severity of DMO. Results: While global NPA at baseline was not correlated to retinal thickness measurements, baseline NPA in the superior retina was associated with the macular volume (MV) improvement (P = 0.022). Multivariate analysis revealed a smaller RVBA at baseline was correlated with a better MV outcome at two-year follow-up after adjusting for confounding factors (P = 0.049). Conclusion: Eyes with smaller baseline RVBA appear to have a better long-term anatomic outcome of DMO.

Original languageEnglish (US)
JournalEye (Basingstoke)
DOIs
StateAccepted/In press - 2022

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Fingerprint

Dive into the research topics of 'Baseline retinal vascular bed area on ultra-wide field fluorescein angiography correlates with the anatomical outcome of diabetic macular oedema to ranibizumab therapy: two-year analysis of the DAVE Study'. Together they form a unique fingerprint.

Cite this